Economic evaluation of a randomised trial of early return to normal activities versus cardiac rehabilitation after acute myocardial infarction.
Hall, Jane P;
Wiseman, Virginia L;
King, Madeleine T;
Ross, David L;
Kovoor, Pramesh;
Zecchin, Robert P;
Moir, Fiona M;
Robert Denniss, A;
(2002)
Economic evaluation of a randomised trial of early return to normal activities versus cardiac rehabilitation after acute myocardial infarction.
Heart, lung & circulation, 11 (1).
pp. 10-18.
ISSN 1443-9506
DOI: https://doi.org/10.1046/j.1444-2892.2002.00105.x
Permanent Identifier
Use this Digital Object Identifier when citing or linking to this resource.
BACKGROUND: Although there have been a number of economic evaluations of cardiac rehabilitation after acute myocardial infarction (AMI), none has considered only low-risk patients or control groups with no rehabilitation at all. METHODS: An economic evaluation was included in a randomised controlled trial of patients following uncomplicated AMI. Eligible patients were randomised to return to normal activities after 6 weeks of standard rehabilitation (REHAB, n = 70) or to early return to normal activities 2 weeks after AMI with no formal rehabilitation (ERNA, n = 72). Outcomes were assessed weekly for 6 weeks, then 3, 6 and 12 months post-AMI. Outcomes included four quality of life (QOL) measures (physical abilities, distress, usual/social activities, self-care) and four measures of return to normal activities (paid and unpaid return to any work and to pre-AMI level of work). Statistical analysis included repeated-measures regression (QOL outcomes) and survival analysis (work outcomes). RESULTS: There were no statistically significant differences between the two groups in any of the outcomes measured or in the use of other health services. The net cost that could be saved by the health service by targeting rehabilitation to high-risk patients was approximately $300 (Australian, 1999) per low-risk patient. CONCLUSIONS: Early return to normal activities without formal rehabilitation is cost-effective for low-risk patients.